SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-038107
Filing Date
2024-02-16
Accepted
2024-02-16 08:30:30
Documents
14
Period of Report
2024-02-14
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 8-K d754358d8k.htm   iXBRL 8-K 31443
  Complete submission text file 0001193125-24-038107.txt   152282

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA allo-20240214.xsd EX-101.SCH 2842
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20240214_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20240214_pre.xml EX-101.PRE 10807
15 EXTRACTED XBRL INSTANCE DOCUMENT d754358d8k_htm.xml XML 3518
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 24645868
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)